Skip to main content

PYPD · PolyPid Ltd. · Documents

Track PYPD — free
$6.26 -0.14 (-2.19%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Market Cap
$132.25M
Shares
21.13M
Volume · Nov 13 193.16K Avg daily vol (3M) 123.95K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $34.17M 20-F filed Feb 25, 2026 Earnings call Q2 2026 earnings call Held Aug 12, 2026
2026
Oct 28
Investor event
PolyPid to Host Virtual Investor Day on Wednesday, October 28, 2026

PolyPid said Deeplex 100 faces a November 28, 2026 PDUFA date, with U.S. launch expected in 2027 if approved. Its Azurdi Pharmaceuticals partnership received $30 million upfront and offers over $290 million in milestones.

Read from the first part of this long document
Oct 28
Current report 6-K
Current report

PolyPid introduced PD01B, a Kynatrix-based doxycycline candidate for diabetic foot infections, targeting a pre-IND meeting and first-in-human study in the second half of 2027. D-PLEX₁₀₀ is under FDA Priority Review with a November 28, 2026 PDUFA goal date.

Oct 1
Current report 6-K
Current report

PolyPid’s D-PLEX₁₀₀ marketing authorization application was validated by the European Medicines Agency, initiating formal review. Its FDA Priority Review has a November 28, 2026 PDUFA goal date, and Phase 3 SHIELD II showed a 60% relative risk reduction (p=0.0013).

Oct 1
Current report 6-K
Current report

PolyPid and ADVANZ PHARMA mutually terminated their 2022 exclusive License, Distribution and Supply Agreement for D-PLEX₁₀₀ in Europe; exclusive European commercialization rights have reverted to PolyPid.

Sep 29
Investor event
Lytham Partners Fall 2026 Investor Conference

PolyPid Ltd reported a November 28th PDUFA date, pivotal 1,000-patient results of 18% to 10.9%, and an Azuriti Pharmaceutical deal providing $30 million upfront and near-term milestones, with sales planned for 2027.

Feb 25
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $34.17M Diluted EPS $2.09 ▼ 57.4%
2025
2024
Showing 1–50 of 162 documents
Key facts CIK 1611842 CUSIP M8001Q126 13F (30d) 18 filings 18 filers Visit website Investor relations